Dr Ye Oo

 

Dr Ye is a Clinician Scientist at University of Birmingham and Honorary Consultant Hepatologist at the UHB NHS Foundation Trust. His research remit is on hepatic immune regulation, gut-liver axis immunopathology and GMP regulatory T cells therapy
Position:

Clinician Scientist, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham. 

Consultant Hepatologist, Liver and Hepatobiliary Unit, University Hospital Birmingham NHS Foundation Trust

UK-AIH Immunology workstream lead

Email: y.h.oo@bham.ac.ukYe.Oo@uhb.nhs.uk

UoB profile

LinkedIn profile

 

Background and Research focus

Ye is a Clinician Scientist with a long-standing research interest in hepatic immune regulation and autoimmune liver diseases. His basic research programme is to dissect and understand the pathogenesis of liver inflammation and repair in autoimmune liver diseases and how to restore the hepatic tolerance, understanding gut & liver immunology and delivering GMP cellular therapy in liver diseases. Collectively, his translational research aims to bridge benchwork laboratory findings to bedside patients care by developing new cellular and cytokine therapies for patients with autoimmune liver diseases and liver transplant recipients. His team just completed first in autoimmune liver diseases GMP Treg study and now utilizing this comprehensive understanding of translational research findings to conduct Phase I, II clinical trials to develop new and novel therapies for patients with liver diseases.

Ye and his research team aim to restore immune homeostasis in autoimmune liver diseases with GMP grade autologous regulatory T cells and cytokines therapy in collaboration with Advanced Therapy Facility, Institute of Translational Medicine and Advanced Therapy Treatment Centre in Birmingham.

 

Expertise

Autoimmune liver diseases; Regulatory T cells biology; Mucosa immunology; GMP cellular therapy

 

Other activities

Ye leads an active and productive basic science and clinical research team with post-doctoral fellows, clinical fellows (UK and Europe), PhD students and intercalated medical students. He also supervises clinical trial research team, research nurses and translational cell therapy group. He receives grant fundings from the MRC, NIHR, Children Liver Disease Foundation, Bowl Disease Research Foundation, EASL and the Queen Elizabeth Hospital Birmingham Charity. He is a national lead for UK-AIH immunology work of UK-AIH Consortium.

In addition to his research commitments, Ye is a Consultant Hepatologist at the Liver Transplant and Hepato-biliary Department at University Hospital Birmingham NHS Foundation Trust. Together with his colleagues, he conducts dedicated autoimmune hepatitis clinics at the Centre for Rare Diseases at Institute of Translational Medicine, post liver transplant viral hepatitis clinics and assess patients for liver transplantation and look after them following transplantation. He is involved in viral vaccine trials and STOP-Colitis trial immunology. In addition, Ye serves as a MRCP Practical Assessment of Clinical Examination Skills (PACES) examiner which involves assessing core clinical skills of junior doctors. He also makes substantial contributions to teaching by delivering regular lectures on autoimmune liver diseases, liver transplantation and hepatic immunology to BMedSc (Medical Science), MSc (in Immunology and Immunotherapy), medical students and MRCP PACES courses at the University of Birmingham. He is the recipient of Sir Frances Avery Jones medal from the British Society of Gastroenterology and also is a core team member of UK-AIH and International Autoimmune Hepatitis Group. Ye is an active member of the British, European and American Associations for study of liver diseases and British Viral Hepatitis Group.

 

Publications

Bhogal RH, Weston CJ, Velduis S, Leuvenink HGD, Reynolds GM, Davies S, Thin LN, Alfaifi M, Shepard E, Boteon Y, Wallace L, Oo Y, Adams DH, Mirza DF, Mergental H, Muirhead G, Stephenson BF, Afford SC. The ROS-Mitophagy Signalling Pathway Regulates Liver Endothelial Cell Survival during Ischaemia-Reperfusion Injury. Liver Transpl. 2018 Jul 24. doi: 10.1002/lt.25313. [Epub ahead of print]

 

Atif M, Warner S, Oo YH. Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells. Hepatol Int. 2018 Jul 19. doi: 10.1007/s12072-018-9882-x. [Epub ahead of print] Review.

 

Hunter S, Willcox CR, Davey MS, Kasatskaya SA, Jeffery HC, Chudakov DM, Oo YH, Willcox BE. Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations. J Hepatol. 2018 May 18. pii: S0168-8278(18)32053-1. doi: 10.1016/j.jhep.2018.05.007. [Epub ahead of print]

 

Davey MS, Willcox CR, Hunter S, Kasatskaya SA, Remmerswaal EBM, Salim M, Mohammed F, Bemelman FJ, Chudakov DM, Oo YH, Willcox BE. The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(-) subsets. Nat Commun. 2018 May 2;9(1):1760. doi: 10.1038/s41467-018-04076-0.

 

Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, Oo YH, Mells G, Kendrick S, Dyson JK, Jones DEJ; UK-AIH Consortium. The Impact of Autoimmune Hepatitis and its Treatment on Health Utility. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30031. [Epub ahead of print]

 

Jeffery HC, Braitch MK, Bagnall C, Hodson J, Jeffery LE, Wawman RE, Wong LL, Birtwistle J, Bartlett H, Lohse AW, Hirschfield GM, Dyson J, Jones D, Hubscher SG, Klenerman P, Adams DH, Oo YH. Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. Hepatol Commun. 2018 Feb 26;2(4):421-436. doi: 10.1002/hep4.1163. eCollection 2018 Apr.

 

Wawman RE, Bartlett H, Oo YH. Regulatory T Cell Metabolism in the Hepatic Microenvironment. Front Immunol. 2018 Jan 8;8:1889. doi: 10.3389/fimmu.2017.01889. eCollection 2017. Review.

 

Jeffery HC, McDowell P, Lutz P, Wawman RE, Roberts S, Bagnall C, Birtwistle J, Adams DH, Oo YH. Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score. PLoS One. 2017 Dec 19;12(12):e0188649. doi: 10.1371/journal.pone.0188649. eCollection 2017.

 

Riva A, Patel V, Kurioka A, Jeffery HC, Wright G, Tarff S, Shawcross D, Ryan JM, Evans A, Azarian S, Bajaj JS, Fagan A, Patel V, Mehta K, Lopez C, Simonova M, Katzarov K, Hadzhiolova T, Pavlova S, Wendon JA, Oo YH, Klenerman P, Williams R,  Chokshi S. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut. 2018May;67(5):918-930. doi: 10.1136/gutjnl-2017-314458. Epub 2017 Nov 2.

 

Lwin AT, Lwin T, Naing P, Oo Y, Kidd D, Cerullo M, Posen J, Hlaing K, Yenokyan G, Thinn KK, Soe ZW, Stevens KA. Self-Directed Interactive Video-Based Instruction Versus Instructor-Led Teaching for Myanmar House Surgeons: A Randomized, Noninferiority Trial. J Surg Educ. 2018 Jan – Feb;75(1):238-246. doi: 10.1016/j.jsurg.2017.06.004. Epub 2017 Jun 29.